New hope for walking again? drug trial tests mobility aid for rare nerve disease
NCT ID NCT02868567
Summary
This study is testing whether a drug called dalfampridine can improve walking speed and quality of life for people with primary lateral sclerosis (PLS), a rare nerve disease that affects movement. Over 18 weeks, 35 participants with PLS will take the drug while researchers measure how fast they can walk 25 feet and how they feel. The main goal is to see if the drug is safe and if it consistently helps people walk faster compared to when they're not taking it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MOTOR NEURON DISEASE, UPPER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mass General Hospital
Boston, Massachusetts, 02114, United States
-
Shara Holzberg
New York, New York, 10021, United States
-
University of Florida Gainsville
Gainesville, Florida, 32607, United States
Conditions
Explore the condition pages connected to this study.